Speaker
Description
Tuberculosis (TB), a contagious infection caused by Mycobacterium tuberculosis, poses a severe risk to public health. This airborne infection is becoming more complex in the upcoming days. Therefore, controlling such multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) has become difficult. The MDR-TB is developed when the strain become resistant to isoniazid and rifampicin. Surprisingly, people receiving treatment for MDR-TB may develop XDR-TB and then the microbes show resistance to fluoroquinolones and one or more than one injectable drugs. Development of this resistance may occur by intrinsic or acquired mechanisms, which could be detected by polymerase chain reaction, ligase chain reaction, or line probe assay. Such resistance to TB conditions affects both developed and underdeveloped regions worldwide. With current chemotherapeutic drugs, XDR-TB is frequently seen as exceedingly difficult to treat or perhaps incurable and these drugs are also costly. On the other hand, these agents possess severe toxic effects. Recent knowledge in the developmental process of such resistance in the microorganisms provides avenues to bring novel therapeutics; however, limited numbers of available treatments urge society to improve awareness of such development.